Top

Current Neurology and Neuroscience Reports

Published in:

28-02-2024 | Multiple Sclerosis | Review

The Impact of Aging on Multiple Sclerosis

Authors: Christopher E. Goyne, Ashley E. Fair, Paige E. Sumowski, Jennifer S. Graves

Published in: Current Neurology and Neuroscience Reports | Issue 4/2024

Abstract

Purpose of Review

Multiple sclerosis (MS) is a chronic, immune-mediated demyelinating disorder of the central nervous system. Age is one of the most important factors in determining MS phenotype. This review provides an overview of how age influences MS clinical characteristics, pathology, and treatment.

Recent findings

New methods for measuring aging have improved our understanding of the aging process in MS. New studies have characterized the molecular and cellular composition of chronic active or smoldering plaques in MS. These lesions are important contributors to disability progression in MS. These studies highlight the important role of immunosenescence and the innate immune system in sustaining chronic inflammation. Given these changes in immune function, several studies have assessed optimal treatment strategies in aging individuals with MS.

Summary

MS phenotype is intimately linked with chronologic age and immunosenescence. While there are many unanswered questions, there has been much progress in understanding this relationship which may lead to more effective treatments for progressive disease.

Ropper AH, Samuels MA, Klein J. Adams and Victor’s principles of neurology. Eleventh. New York: McGraw-Hill Education; 2019.

Wallin MT, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurol. 2019;92(10):e1029–40. https://doi.org/10.1212/WNL.0000000000007035.CrossRef

Kuhlmann T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023;22(1):78–88. https://doi.org/10.1016/S1474-4422(22)00289-7.CrossRefPubMed

Stankoff B, et al. Age at onset determines the occurrence of the progressive phase of multiple sclerosis. Neurol. 2007;68(10):779–81. https://doi.org/10.1212/01.wnl.0000256732.36565.4a.CrossRef

M. P. Gorman, B. C. Healy, M. Polgar-Turcsanyi, and T. Chitnis, “Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple Sclerosis,” Arch. Neurol., vol. 66, no. 1, 2009, https://doi.org/10.1001/archneurol.2008.505.

Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology. 2011;77(13):1246–52. https://doi.org/10.1212/WNL.0b013e318230a17d.CrossRefPubMedPubMedCentral

Harding KE, et al. Long-term outcome of paediatric-onset multiple sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2013;84(2):141–7. https://doi.org/10.1136/jnnp-2012-303996.CrossRefPubMed

Tutuncu M, et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler J. 2013;19(2):188–98. https://doi.org/10.1177/1352458512451510.CrossRef

E. Waubant et al., “Difference in Disease Burden and Activity in Pediatric Patients on Brain Magnetic Resonance Imaging at Time of Multiple Sclerosis Onset vs Adults,” Arch Neurol., vol. 66, no. 8, 2009, https://doi.org/10.1001/archneurol.2009.135.

10.

Pfeifenbring S, et al. Extensive acute axonal damage in pediatric multiple sclerosis lesions. Ann Neurol. 2015;77(4):655–67. https://doi.org/10.1002/ana.24364.CrossRefPubMedPubMedCentral

11.

Tremlett H, Zhao Y, Joseph J, Devonshire V, the UBCMS Clinic Neurologists. 2“Relapses in multiple sclerosis are age- and time-dependent.” J Neurol Neurosurg Psychiatry. 2008;79(12):1368–74. https://doi.org/10.1136/jnnp.2008.14580.CrossRefPubMed

12.

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707–17. https://doi.org/10.1002/1531-8249(200006)47:6%3c707::AID-ANA3%3e3.0.CO;2-Q.CrossRefPubMed

13.

Frischer JM, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78(5):710–21. https://doi.org/10.1002/ana.24497.CrossRefPubMedPubMedCentral

14.

Jäckle K, et al. Molecular signature of slowly expanding lesions in progressive multiple sclerosis. Brain. 2020;143(7):2073–88. https://doi.org/10.1093/brain/awaa158.CrossRefPubMed

15.

• M. Absinta et al., “A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis,” Nature, vol. 597, no. 7878, pp. 709–714, 2021https://doi.org/10.1038/s41586-021-03892-7This study describes a genetic profile of disease associated microglia in MS.

16.

Nicaise AM, et al. Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis. Proc Natl Acad Sci. 2019;116(18):9030–9. https://doi.org/10.1073/pnas.1818348116.ADSCrossRefPubMedPubMedCentral

17.

• A. Calvi et al., “Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis,” Mult Scler J., vol. 29, no. 3, pp. 352–362, Mar. 2023https://doi.org/10.1177/13524585221141964This study describes paramagnetic rim and slowly expanding lesions in multiple sclerosis and reports association with progression.•

18.

Elliott C, et al. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain. 2019;142(9):2787–99. https://doi.org/10.1093/brain/awz212.CrossRefPubMedPubMedCentral

19.

P. Maggi et al., “Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis,” Neurology, vol. 97, no. 6, 2021, https://doi.org/10.1212/WNL.0000000000012326.

20.

Absinta M, et al. Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. JAMA Neurol. 2019;76(12):1474. https://doi.org/10.1001/jamaneurol.2019.2399.CrossRefPubMedPubMedCentral

21.

Absinta M, et al. Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest. 2016;126(7):2597–609. https://doi.org/10.1172/JCI86198.CrossRefPubMedPubMedCentral

22.

Vollmer T, et al. The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis. J Neurol Sci. 2015;357(1–2):8–18. https://doi.org/10.1016/j.jns.2015.07.014.CrossRefPubMed

23.

Azevedo CJ, Cen SY, Jaberzadeh A, Zheng L, Hauser SL, Pelletier D. Contribution of normal aging to brain atrophy in MS. Neurol Neuroimmunol Neuroinflammation. 2019;6(6): e616. https://doi.org/10.1212/NXI.0000000000000616.CrossRef

24.

Zhang J, et al. Gray matter atrophy cannot be fully explained by white matter damage in patients with MS. Mult Scler J. 2021;27(1):39–51. https://doi.org/10.1177/1352458519900972.CrossRef

25.

M. A. Rocca et al., “Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis,” Neurology, vol. 96, no. 11, 2021, https://doi.org/10.1212/WNL.0000000000011494.

26.

Bø L, Vedeler CA, Nyland HI, Trapp BD, Mørk SJ. Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients. J Neuropathol Exp Neurol. 2003;62(7):723–32. https://doi.org/10.1093/jnen/62.7.723.CrossRefPubMed

27.

Bell L, Lenhart A, Rosenwald A, Monoranu CM, Berberich-Siebelt F. Lymphoid Aggregates in the CNS of Progressive Multiple Sclerosis Patients Lack Regulatory T Cells. Front Immunol. 2020;10:3090. https://doi.org/10.3389/fimmu.2019.03090.CrossRefPubMedPubMedCentral

28.

Van Olst L, et al. Meningeal inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially associate with neurodegeneration. Acta Neuropathol (Berl). 2021;141(6):881–99. https://doi.org/10.1007/s00401-021-02293-4.CrossRefPubMed

29.

Levine ME. Modeling the Rate of Senescence: Can Estimated Biological Age Predict Mortality More Accurately Than Chronological Age? J Gerontol A Biol Sci Med Sci. 2013;68(6):667–74. https://doi.org/10.1093/gerona/gls233.CrossRefPubMed

30.

Blackburn EH, Epel ES, Lin J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. Science. 2015;350(6265):1193–8. https://doi.org/10.1126/science.aab3389.ADSCrossRefPubMed

31.

Krysko KM, et al. Telomere Length Is Associated with Disability Progression in Multiple Sclerosis. Ann Neurol. 2019;86(5):671–82. https://doi.org/10.1002/ana.25592.CrossRefPubMedPubMedCentral

32.

Musella A, et al. Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions. Front Aging Neurosci. 2018;10:238. https://doi.org/10.3389/fnagi.2018.00238.CrossRefPubMedPubMedCentral

33.

R. G. Morgan, A. J. Donato, and A. E. Walker, “Telomere uncapping and vascular aging,” Am J Physiol-Heart Circ Physiol., vol. 315, no. 1, pp. H1–H5, 2018, https://doi.org/10.1152/ajpheart.00008.2018.

34.

M. A. Giardini, M. Segatto, M. S. Da Silva, V. S. Nunes, and M. I. N. Cano, “Telomere and Telomerase Biology,” in Progress in Molecular Biology and Translational Science, vol. 125, Elsevier, 2014, pp. 1–40. https://doi.org/10.1016/B978-0-12-397898-1.00001-3.

35.

Goglin SE, Farzaneh-Far R, Epel ES, Lin J, Blackburn EH, Whooley MA. Change in Leukocyte Telomere Length Predicts Mortality in Patients with Stable Coronary Heart Disease from the Heart and Soul Study. PLoS ONE. 2016;11(10): e0160748. https://doi.org/10.1371/journal.pone.0160748.CrossRefPubMedPubMedCentral

36.

Willeit P, et al. Cellular Aging Reflected by Leukocyte Telomere Length Predicts Advanced Atherosclerosis and Cardiovascular Disease Risk. Arterioscler Thromb Vasc Biol. 2010;30(8):1649–56. https://doi.org/10.1161/ATVBAHA.110.205492.CrossRefPubMed

37.

Topiwala A, et al. Alcohol consumption and telomere length: Mendelian randomization clarifies alcohol’s effects. Mol Psychiatry. 2022;27(10):4001–8. https://doi.org/10.1038/s41380-022-01690-9.CrossRefPubMedPubMedCentral

38.

Galiè S, Canudas S, Muralidharan J, García-Gavilán J, Bulló M, Salas-Salvadó J. Impact of Nutrition on Telomere Health: Systematic Review of Observational Cohort Studies and Randomized Clinical Trials. Adv Nutr. 2020;11(3):576–601. https://doi.org/10.1093/advances/nmz107.CrossRefPubMed

39.

Song S, Lee E, Kim H. Does Exercise Affect Telomere Length? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina (Mex). 2022;58(2):242. https://doi.org/10.3390/medicina58020242.CrossRef

40.

Khosravaniardakani S, et al. Obesity Accelerates Leukocyte Telomere Length Shortening in Apparently Healthy Adults: A Meta-Analysis. Front Nutr. 2022;9: 812846. https://doi.org/10.3389/fnut.2022.812846.CrossRefPubMedPubMedCentral

41.

Astuti Y, Wardhana A, Watkins J, Wulaningsih W. Cigarette smoking and telomere length: A systematic review of 84 studies and meta-analysis. Environ Res. 2017;158:480–9. https://doi.org/10.1016/j.envres.2017.06.038.CrossRefPubMedPubMedCentral

42.

Gardner M, et al. Gender and telomere length: Systematic review and meta-analysis. Exp Gerontol. 2014;51:15–27. https://doi.org/10.1016/j.exger.2013.12.004.CrossRefPubMed

43.

Needham BL, Salerno S, Roberts E, Boss J, Allgood KL, Mukherjee B. Do black/white differences in telomere length depend on socioeconomic status? Biodemography Soc Biol. 2020;65(4):287–312. https://doi.org/10.1080/19485565.2020.1765734.CrossRef

44.

Benetos A, Aviv A. Ancestry, Telomere Length, and Atherosclerosis Risk. Circ Cardiovasc Genet. 2017;10(3): e001718. https://doi.org/10.1161/CIRCGENETICS.117.001718.CrossRefPubMedPubMedCentral

45.

Habib R, Ocklenburg S, Hoffjan S, Haghikia A, Epplen JT, Arning L. Association between shorter leukocyte telomeres and multiple sclerosis. J Neuroimmunol. 2020;341: 577187. https://doi.org/10.1016/j.jneuroim.2020.577187.CrossRefPubMed

46.

Hecker M, et al. Leukocyte Telomere Length in Patients with Multiple Sclerosis and Its Association with Clinical Phenotypes. Mol Neurobiol. 2021;58(6):2886–96. https://doi.org/10.1007/s12035-021-02315-y.CrossRefPubMedPubMedCentral

47.

Redondo J, et al. Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro. Mult Scler J. 2018;24(7):919–31. https://doi.org/10.1177/1352458517711276.CrossRef

48.

Shireby GL, et al. Recalibrating the epigenetic clock: implications for assessing biological age in the human cortex. Brain. 2020;143(12):3763–75. https://doi.org/10.1093/brain/awaa334.CrossRefPubMedPubMedCentral

49.

Levine ME, Lu AT, Bennett DA, Horvath S. Epigenetic age of the pre-frontal cortex is associated with neuritic plaques, amyloid load, and Alzheimer’s disease related cognitive functioning. Aging. 2015;7(12):1198–211. https://doi.org/10.18632/aging.100864.CrossRefPubMedPubMedCentral

50.

Kular L, et al. Epigenetic clock indicates accelerated aging in glial cells of progressive multiple sclerosis patients. Front Aging Neurosci. 2022;14: 926468. https://doi.org/10.3389/fnagi.2022.926468.CrossRefPubMedPubMedCentral

51.

• V. Maltby et al., “Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis,” Neurology, vol. 101, no. 7, 2023, https://doi.org/10.1212/WNL.0000000000207489. This study describes accelerated epigenetic aging within B cells in MS.

52.

Pearce EE, et al. Telomere length and epigenetic clocks as markers of cellular aging: a comparative study. GeroScience. 2022;44(3):1861–9. https://doi.org/10.1007/s11357-022-00586-4.CrossRefPubMedPubMedCentral

53.

Marioni RE, et al. The epigenetic clock and telomere length are independently associated with chronological age and mortality. Int J Epidemiol. 2016;45(2):424–32. https://doi.org/10.1093/ije/dyw041.CrossRefPubMedPubMedCentral

54.

• A. E. Miner, J. H. Yang, R. P. Kinkel, and J. S. Graves, “The NHANES Biological Age Index demonstrates accelerated aging in MS patients,” Mult Scler Relat Disord., vol. 77, p. 104859, 2023 https://doi.org/10.1016/j.msard.2023.104859This study uses biologic aging index utilizing common laboratory findings to show accelerated aging in MS patients.•

55.

Aiello A, et al. Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. Front Immunol. 2019;10:2247. https://doi.org/10.3389/fimmu.2019.02247.CrossRefPubMedPubMedCentral

56.

Mogilenko DA, et al. Comprehensive Profiling of an Aging Immune System Reveals Clonal GZMK+ CD8+ T Cells as Conserved Hallmark of Inflammaging. Immunity. 2021;54(1):99-115.e12. https://doi.org/10.1016/j.immuni.2020.11.005.CrossRefPubMed

57.

Thewissen M, et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin Immunol. 2007;123(2):209–18. https://doi.org/10.1016/j.clim.2007.01.005.CrossRefPubMed

58.

Eschborn M, et al. Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis. Neurol Neuroimmunol Neuroinflammation. 2021;8(6): e1094. https://doi.org/10.1212/NXI.0000000000001094.CrossRef

59.

Thewissen M, Linsen L, Somers V, Geusens P, Raus J, Stinissen P. Premature Immunosenescence in Rheumatoid Arthritis and Multiple Sclerosis Patients. Ann N Y Acad Sci. 2005;1051(1):255–62. https://doi.org/10.1196/annals.1361.066.ADSCrossRefPubMed

60.

Claes N, et al. Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis Patients. J Immunol. 2016;197(12):4576–83. https://doi.org/10.4049/jimmunol.1502448.CrossRefPubMed

61.

Greenwood EK, Brown DR. Senescent Microglia: The Key to the Ageing Brain? Int J Mol Sci. 2021;22(9):4402. https://doi.org/10.3390/ijms22094402.CrossRefPubMedPubMedCentral

62.

Ng PY, McNeely TL, Baker DJ. Untangling senescent and damage-associated microglia in the aging and diseased brain. FEBS J. 2023;290(5):1326–39. https://doi.org/10.1111/febs.16315.CrossRefPubMed

63.

Oost W, Talma N, Meilof JF, Laman JD. Targeting senescence to delay progression of multiple sclerosis. J Mol Med. 2018;96(11):1153–66. https://doi.org/10.1007/s00109-018-1686-x.CrossRefPubMed

64.

Norden DM, Godbout JP. Review: Microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol. 2013;39(1):19–34. https://doi.org/10.1111/j.1365-2990.2012.01306.x.CrossRefPubMedPubMedCentral

65.

• T. Matsudaira et al., “Cellular senescence in white matter microglia is induced during ageing in mice and exacerbates the neuroinflammatory phenotype,” Commun Biol., vol. 6, no. 1, p. 665, 2023https://doi.org/10.1038/s42003-023-05027-2This study demonstrates cellular senescence in aging microglia and describes the association with disease associated microglia.•

66.

Franklin RJM, ffrench-Constant C. Regenerating CNS myelin — from mechanisms to experimental medicines. Nat Rev Neurosci. 2017;18(12):753–69. https://doi.org/10.1038/nrn.2017.136.CrossRefPubMed

67.

Franklin RJM, Frisén J, Lyons DA. Revisiting remyelination: Towards a consensus on the regeneration of CNS myelin. Semin Cell Dev Biol. 2021;116:3–9. https://doi.org/10.1016/j.semcdb.2020.09.009.CrossRefPubMed

68.

Rist JM, Franklin RJM. Taking ageing into account in remyelination-based therapies for multiple sclerosis. J Neurol Sci. 2008;274(1–2):64–7. https://doi.org/10.1016/j.jns.2008.04.027.CrossRefPubMed

69.

Ruckh JM, et al. Rejuvenation of Regeneration in the Aging Central Nervous System. Cell Stem Cell. 2012;10(1):96–103. https://doi.org/10.1016/j.stem.2011.11.019.CrossRefPubMedPubMedCentral

70.

Sim FJ, Zhao C, Penderis J, Franklin RJM. The Age-Related Decrease in CNS Remyelination Efficiency Is Attributable to an Impairment of Both Oligodendrocyte Progenitor Recruitment and Differentiation. J Neurosci. 2002;22(7):2451–9. https://doi.org/10.1523/JNEUROSCI.22-07-02451.2002.CrossRefPubMedPubMedCentral

71.

Neumann B, et al. Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells. Cell Stem Cell. 2019;25(4):473-485.e8. https://doi.org/10.1016/j.stem.2019.08.015.CrossRefPubMedPubMedCentral

72.

Heß K, et al. Lesion stage-dependent causes for impaired remyelination in MS. Acta Neuropathol (Berl). 2020;140(3):359–75. https://doi.org/10.1007/s00401-020-02189-9.CrossRefPubMed

73.

• C. M. Willis et al., “Astrocyte Support for Oligodendrocyte Differentiation can be Conveyed via Extracellular Vesicles but Diminishes with Age,” Sci Rep., vol. 10, no. 1, p. 828, 2020https://doi.org/10.1038/s41598-020-57663-xThis study shows the importance of astrocyte support in oligodendrocyte differentiation and describes how this declines with age.•

74.

J. Correale and M. F. Farez, “The Role of Astrocytes in Multiple Sclerosis Progression,” Front Neurol., vol. 6, 2015, https://doi.org/10.3389/fneur.2015.00180.

75.

Goldschmidt T, Antel J, König FB, Brück W, Kuhlmann T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology. 2009;72(22):1914–21. https://doi.org/10.1212/WNL.0b013e3181a8260a.CrossRefPubMed

76.

Neumann B, et al. Myc determines the functional age state of oligodendrocyte progenitor cells. Nat Aging. 2021;1(9):826–37. https://doi.org/10.1038/s43587-021-00109-4.CrossRefPubMed

77.

Huang JK, et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat Neurosci. 2011;14(1):45–53. https://doi.org/10.1038/nn.2702.CrossRefPubMed

78.

Segel M, et al. Niche stiffness underlies the ageing of central nervous system progenitor cells. Nature. 2019;573(7772):130–4. https://doi.org/10.1038/s41586-019-1484-9.ADSCrossRefPubMedPubMedCentral

79.

Natrajan MS, et al. Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination. Brain. 2015;138(12):3581–97. https://doi.org/10.1093/brain/awv289.CrossRefPubMedPubMedCentral

80.

Cantuti-Castelvetri L, et al. Defective cholesterol clearance limits remyelination in the aged central nervous system. Science. 2018;359(6376):684–8. https://doi.org/10.1126/science.aan4183.ADSCrossRefPubMed

81.

Rawji KS, et al. Niacin-mediated rejuvenation of macrophage/microglia enhances remyelination of the aging central nervous system. Acta Neuropathol (Berl). 2020;139(5):893–909. https://doi.org/10.1007/s00401-020-02129-7.CrossRefPubMed

82.

Voskuhl RR, Palaszynski K. Sex Hormones in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis. Neuroscientist. 2001;7(3):258–70. https://doi.org/10.1177/107385840100700310.CrossRefPubMed

83.

Krysko KM, et al. Sex effects across the lifespan in women with multiple sclerosis. Ther Adv Neurol Disord. 2020;13:175628642093616. https://doi.org/10.1177/1756286420936166.CrossRef

84.

• K. Borziak and J. Finkelstein, “X-linked genetic risk factors that promote autoimmunity and dampen remyelination are associated with multiple sclerosis susceptibility,” Mult Scler Relat Disord., vol. 66, p. 104065, 2022https://doi.org/10.1016/j.msard.2022.104065This study describes sex linked immune genes that are associated with MS susceptibility.•

85.

Correale J, Arias M, Gilmore W. Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol Baltim Md 1950. 1998;161(7):3365–74.

86.

Soldan SS, Retuerto AIA, Sicotte NL, Voskuhl RR. Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol. J Immunol. 2003;171(11):6267–74. https://doi.org/10.4049/jimmunol.171.11.6267.CrossRefPubMed

87.

Magyari M. Role of socio-economic and reproductive factors in the risk of multiple sclerosis. Acta Neurol Scand. 2015;132:20–3. https://doi.org/10.1111/ane.12426.CrossRefPubMed

88.

Bove R, Healy BC, Musallam A, Glanz BI, De Jager PL, Chitnis T. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler J. 2016;22(7):935–43. https://doi.org/10.1177/1352458515606211.CrossRef

89.

Baroncini D, et al. Impact of natural menopause on multiple sclerosis: a multicentre study. J Neurol Neurosurg Psychiatry. 2019;90(11):1201–6. https://doi.org/10.1136/jnnp-2019-320587.CrossRefPubMed

90.

Zeydan B, et al. Reproductive history and progressive multiple sclerosis risk in women. Brain Commun. 2020;2(2):fcaa185. https://doi.org/10.1093/braincomms/fcaa185.CrossRefPubMedPubMedCentral

91.

J. S. Graves et al., “Ovarian aging is associated with gray matter volume and disability in women with MS,” Neurology, vol. 90, no. 3, 2018, https://doi.org/10.1212/WNL.0000000000004843.

92.

Marrie RA, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010;74(13):1041–7. https://doi.org/10.1212/WNL.0b013e3181d6b125.CrossRefPubMedPubMedCentral

93.

Tettey P, et al. Frequency of Comorbidities and Their Association with Clinical Disability and Relapse in Multiple Sclerosis. Neuroepidemiology. 2016;46(2):106–13. https://doi.org/10.1159/000442203.CrossRefPubMed

94.

Kowalec K, et al. Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study. Neurology. 2017;89(24):2455–61. https://doi.org/10.1212/WNL.0000000000004716.CrossRefPubMedPubMedCentral

95.

Marrie RA, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Mult Scler J. 2015;21(3):263–81. https://doi.org/10.1177/1352458514564491.CrossRef

96.

Palladino R, Marrie RA, Majeed A, Chataway J. Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England. JAMA Neurol. 2020;77(7):820. https://doi.org/10.1001/jamaneurol.2020.0664.CrossRefPubMed

97.

Geraldes R, et al. Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020;91(4):388–91. https://doi.org/10.1136/jnnp-2019-322369.CrossRefPubMed

98.

Cross A, Riley C. Treatment of Multiple Sclerosis. Contin Lifelong Learn Neurol. 2022;28(4):1025–51. https://doi.org/10.1212/CON.0000000000001170.CrossRef

99.

Horton DB, Reder AT. Medications for Multiple Sclerosis and Risk of Malignancy: What Next? Neurotherapeutics. 2021;18(3):1650–3. https://doi.org/10.1007/s13311-021-01107-5.CrossRefPubMedPubMedCentral

100.

Grytten N, et al. Incidence of cancer in multiple sclerosis before and after the treatment era– a registry- based cohort study. Mult Scler Relat Disord. 2021;55: 103209. https://doi.org/10.1016/j.msard.2021.103209.CrossRefPubMed

101.

P. A. Groome et al., “Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer,” Neurology, vol. 98, no. 18, 2022, https://doi.org/10.1212/WNL.0000000000200163.

102.

Montalban X, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209–20. https://doi.org/10.1056/NEJMoa1606468.CrossRefPubMed

103.

Kappos L, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. The Lancet. 2018;391(10127):1263–73. https://doi.org/10.1016/S0140-6736(18)30475-6.CrossRef

104.

Lublin FD, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014;83(3):278–86. https://doi.org/10.1212/WNL.0000000000000560.CrossRefPubMedPubMedCentral

105.

Hawker K, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460–71. https://doi.org/10.1002/ana.21867.CrossRefPubMed

106.

Holmén C, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler J. 2011;17(6):708–19. https://doi.org/10.1177/1352458510394701.CrossRef

107.

Wijnands JM, et al. Infection-related health care utilization among people with and without multiple sclerosis. Mult Scler J. 2017;23(11):1506–16. https://doi.org/10.1177/1352458516681198.CrossRef

108.

Yano H, Gonzalez C, Healy BC, Glanz BI, Weiner HL, Chitnis T. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Mult Scler Relat Disord. 2019;35:119–27. https://doi.org/10.1016/j.msard.2019.07.021.CrossRefPubMed

109.

Hua LH, Fan TH, Conway D, Thompson N, Kinzy TG. Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60. Mult Scler J. 2019;25(5):699–708. https://doi.org/10.1177/1352458518765656.CrossRef

110.

Coerver EME, et al. Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis. Mult Scler Relat Disord. 2023;74: 104706. https://doi.org/10.1016/j.msard.2023.104706.CrossRefPubMed

111.

• J. R. Corboy et al., “Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial,” Lancet Neurol., vol. 22, no. 7, pp. 568–577,2023https://doi.org/10.1016/S1474-4422(23)00154-0This is the first randomized controlled trial assessing DMT discontinuation in MS patients over age 55.•

Title: The Impact of Aging on Multiple Sclerosis
Authors: Christopher E. Goyne
Ashley E. Fair
Paige E. Sumowski
Jennifer S. Graves
Publication date: 28-02-2024
Publisher: Springer US
Keywords: Multiple Sclerosis
Neurologic Therapy
Published in: Current Neurology and Neuroscience Reports / Issue 4/2024
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-024-01333-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Impact of Aging on Multiple Sclerosis

Abstract

Purpose of Review

Recent findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent findings

Summary

Please log in to get access to this content